Incremental Prognostic Values of Serum Tenascin-C Levels With Blood B-type Natriuretic Peptide Testing at Discharge in Patients With Dilated Cardiomyopathy and Decompensated Heart Failure

Journal of Cardiac Failure

Volumn 15, Issue 10, 2009, Pages 898-905

  Fujimoto, Naoki ^a   Onishi, Katsuya ^a   Sato, Akira ^b   Terasaki, Fumio ^c   Tsukada, Bin ^c   Nozato, Toshihiro ^b   Yamada, Tomomi ^a   Imanaka Yoshida, Kyoko ^a   Yoshida, Toshimichi ^a   Ito, Masaaki ^a   Hiroe, Michiaki ^d  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b YOKOSUKA KYOSAI HOSPITAL   (Japan)

^c OSAKA MEDICAL COLLEGE   (Japan)

^d NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

B type natriuretic peptide; dilated cardiomyopathy; prognosis; Tenascin C

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; TENASCIN;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONGESTIVE CARDIOMYOPATHY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HEART FUNCTION; HEART HEMODYNAMICS; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SUDDEN DEATH; TISSUE REGENERATION;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOMYOPATHY, DILATED; FEMALE; FOLLOW-UP STUDIES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PATIENT DISCHARGE; PROGNOSIS; SURVIVAL RATE; TENASCIN;

EID: 70450255075     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2009.06.443     Document Type: Article

References (34)

1. Schaper J., Froede R., Hein S., Buck A., Hashizume H., Speiser B., et al. Impairment of the myocardial ultrastructure and changes of the cytoskeleton in dilated cardiomyopathy. Circulation 83 (1991) 504-514
2. Nadal-Ginard B., Kajstura J., Leri A., and Anversa P. Myocyte death, growth, and regeneration in cardiac hypertrophy and failure. Circ Res 92 (2003) 139-150
3. Brower G.L., Gardner J.D., Forman M.F., Murray D.B., Voloshenyuk T., Levick S.P., et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg 30 (2006) 604-610
4. Hunt S.A., Abraham W.T., Chin M.H., Feldman A.M., Francis G.S., Ganiats T.G., et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic HF in the adult: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (writing committee to update the 2001 guidelines for the evaluation and management of heart failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112 (2005) e154-e235
5. Tang W.H., Francis G.S., Morrow D.A., Newby L.K., Cannon C.P., Jesse R.L., et al. National Academy of Clinical Biochemistry Laboratory Medicine practice guidelines: clinical utilization of cardiac biomarker testing in heart failure. Circulation 116 (2007) e99-e109
6. Chiquet-Ehrismann R., and Tucker R.P. Connective tissues: signalling by tenascins. Int J Biochem Cell Biol 36 (2004) 1085-1089
7. Orend G., and Chiquet-Ehrismann R. Tenascin-C induced signaling in cancer. Cancer Lett 244 (2006) 143-146
8. Imanaka-Yoshida K., Hiroe M., Nishikawa T., Ishiyama S., Shimojo T., Ohta Y., et al. Tenascin-C modulates adhesion of cardiomyocytes to extracellular matrix during tissue remodeling after myocardial infarction. Lab Invest 81 (2001) 1015-1024
9. Sato A., Aonuma K., Imanaka-Yoshida K., Yoshida T., Isobe M., Kawase D., et al. Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction. J Am Coll Cardiol 47 (2006) 2319-2325
10. Imanaka-Yoshida K., Hiroe M., Yasutomi Y., Toyozaki T., Tsuchiya T., Noda N., et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 197 (2002) 388-394
11. Morimoto S., Imanaka-Yoshida K., Hiramitsu S., Kato S., Ohtsuki M., Uemura A., et al. Diagnostic utility of tenascin-C for evaluation of the activity of human acute myocarditis. J Pathol 205 (2005) 460-467
12. Frangogiannis N.G., Shimoni S., Chang S., Ren G., Dewald O., Gersch C., et al. Active interstitial remodeling: an important process in the hibernating human myocardium. J Am Coll Cardiol 39 (2002) 1468-1474
13. Tamura A., Kusachi S., Nogami K., Yamanishi A., Kajikawa Y., Hirohata S., et al. Tenascin expression in endomyocardial biopsy specimens in patients with dilated cardiomyopathy: distribution along margin of fibrotic lesions. Heart 75 (1996) 291-294
14. Aso N., Tamura A., and Nasu M. Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 94 (2004) 1468-1470
15. Terasaki F., Okamoto H., Onishi K., Sato A., Shimomura H., Tsukada B., et al. Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy. Circ J 71 (2007) 327-330
16. Richardson P., Mckenna W., Bristow M., Maisch B., Mautner B., O'Connell J., et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation 93 (1996) 841-842
17. Fujimoto N., Onishi K., Tanabe M., Dohi K., Funabiki K., Kurita T., et al. Nitroglycerin improves left ventricular relaxation by changing systolic loading sequence in patients with excessive arterial load. J Cardiovasc Pharmacol 45 (2005) 211-216
18. Hasegawa M., Hirata H., Sudo A., Kato K., Kawase D., Kinoshita N., et al. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 31 (2004) 2021-2026
19. Stevens L., Coresh J., Greene T., and Levey A.S. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 354 (2006) 2473-2483
20. Logeart D., Thabut G., Jourdain P., Chavelas C., Beyne P., Beauvais F., et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43 (2004) 635-641
21. Dokainish H., Zoghbi W.A., Lakkis N.M., Ambriz E., Patel R., Quinones M.A., et al. Incremental predictive power of B-type natriuretic peptide and tissue Doppler echocardiography in the prognosis of patients with congestive heart failure. J Am Coll Cardiol 45 (2005) 1223-1226
22. Dries D.L., Exner D.V., Domanski M.J., Greenberg B., and Stevenson L.W. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with let ventricular systolic dysfunction. J Am Coll Cardiol 35 (2000) 681-689
23. Imanaka-Yoshida K., Hiroe M., and Yoshida T. Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling. Histol Hisopathol 19 (2004) 517-525
24. Kalembeyi I., Inada H., Nishiura R., Imanaka-Yoshida K., Sakakura T., and Yoshida T. Tenascin-C upregulates matrix metalloproteinase-9 in breast cancer cells: direct and synergistic effects with transforming growth factor. Int J Cancer 105 (2003) 53-60
25. Nishioka T., Suzuki M., Onishi K., Takakura N., Inada H., Yoshida T., et al. Eplerenone attenuates myocardial fibrosis in the angiotensin ii-induced hypertensive mouse: involvement of tenascin-c induced by aldosterone-mediated inflammation. J Cardiovasc Pharmacol 49 (2007) 261-268
26. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87 (2007) 1285-1342
27. Dhingra R., Pencina M.J., Schrader P., Wang T.J., Levy D., Pencina K., et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation 119 (2009) 1101-1107
28. Emdin M., Vittorini S., Passino C., and Clerico A. Old and new biomarkers of heart failure. Eur J Heart Fail 11 (2009) 331-335
29. Jones P.L., Chapodos R., Baldwin H.S., Raff G.W., Vitvitsky E.V., Spray T.L., et al. Altered hemodynamics controls matrix metalloproteinase activity and tenascin-C expression in neonatal pig lung. Am J Physiol Lung Cell Mol Physiol 282 (2002) L26-L35
30. Ihida-Stansbury K., McKean D.M., Lane K.B., Loyd J.E., Wheeler L.A., Morrell N.W., et al. Tenascin-C is induced by mutated BMP type II receptors in familial forms of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 291 (2006) L694-L702
31. Hörstrup J.H., Gehrmann M., Schneider B., Plöger A., Froese P., Schirop T., et al. Elevation of serum and urine levels of TIMP-1 and tenascin in patients with renal disease. Nephrol Dial Transplant 17 (2002) 1005-1013
32. Nishii M., Inomata T., Takehana H., Naruke T., Yanagisawa T., Moriguchi M., et al. Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure. J Am Coll Cardiol 51 (2008) 2329-2335
33. Mahon N.G., Blackstone E.H., Francis G.S., Starling III R.C., Young J.B., and Lauer M.S. The prognostic value of estimated creatinine clearance alongside functional capacity in patients with chronic congestive heart failure. J Am Coll Cardiol 40 (2002) 1106-1113
34. Hillege H.L., Girbes A.R., de Kam P.J., Boomsma F., de Zeeuw D., Charlesworth A., et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102 (2000) 203-210